Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan

BIOXYTRAN, INC

Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.
NDPD held patents for PLM (PHGG) to treat COVID-19 and 60+ viruses; appraised asset value $15.85M including license.
Related-party accounting (ASC 805-50) requires purchase price of $12.47M to be eliminated against equity, not recorded as assets.
CFO Ola Soderquist adopted a 10b5-1 plan to sell up to 500,000 shares by Dec 31, 2025, contingent on price thresholds.
NDPD was beneficially owned by company officers; transaction approved by board as a related-party acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.